Recombinant Rhesus monkey VEGFC Protein, His-tagged
Cat.No. : | VEGFC-5153R |
Product Overview : | Recombinant Rhesus monkey VEGFC full length or partial length protein was expressed. |
- Specification
- Gene Information
- Related Products
Source : | Mammalian Cells |
Species : | Rhesus monkey |
Tag : | His |
Endotoxin : | < 1.0 EU per μg of the protein as determined by the LAL method. |
Purity : | >80% |
Notes : | This item requires custom production and lead time is between 5-9 weeks. We can custom produce according to your specifications. |
Storage : | Store it at +4 ºC for short term. For long term storage, store it at -20 ºC~-80 ºC. |
Storage Buffer : | PBS buffer |
Gene Name : | VEGFC vascular endothelial growth factor C [ Macaca mulatta (Rhesus monkey) ] |
Official Symbol : | VEGFC |
Synonyms : | VEGFC; vascular endothelial growth factor C; |
Gene ID : | 699502 |
mRNA Refseq : | NM_001136099 |
Protein Refseq : | NP_001129571 |
MIM : | |
UniProt ID : | B6EBK4 |
Products Types
◆ Recombinant Protein | ||
VEGFC-6171R | Recombinant Rat VEGFC Protein, His (Fc)-Avi-tagged | +Inquiry |
VEGFC-10009M | Recombinant Mouse VEGFC Protein, His (Fc)-Avi-tagged | +Inquiry |
Vegfc-5535M | Recombinant Mouse Vascular Endothelial Growth Factor C | +Inquiry |
VEGFC-108H | Active Recombinant Human VEGFC Protein | +Inquiry |
VEGFC-1319M | Acitve Recombinant Mouse/Rat VEGFC protein(Ala108-Arg223), Fc-tagged | +Inquiry |
◆ Lysates | ||
VEGFC-1306RCL | Recombinant Rat VEGFC cell lysate | +Inquiry |
VEGFC-2768HCL | Recombinant Human VEGFC cell lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (7)
Ask a questionVEGFC primarily signals through its interactions with VEGFR-2 (Vascular Endothelial Growth Factor Receptor 2) and VEGFR-3. Upon binding to one of these receptors, VEGFC triggers receptor dimerization, leading to the activation of intracellular signaling pathways. This activation involves phosphorylation events and subsequent recruitment of downstream effectors, which ultimately regulate cellular responses such as proliferation, migration, and angiogenesis. The intricate signaling mechanisms underlying VEGFC-receptor interactions contribute to its functional versatility and provide potential targets for therapeutic interventions.
VEGFC protein is derived from the conversion of proVEGFC precursor protein and comprises approximately 354 amino acid residues. Structurally, it consists of a signal sequence, an N-terminal domain, and a C-terminal VEGF homology domain. The signal sequence is involved in cellular localization and secretion processes, while the VEGF homology domain interacts with target receptors, mediating cellular proliferation and angiogenesis. Understanding the specific structural features is crucial for elucidating the functional properties and molecular interactions associated with VEGFC.
VEGFC's involvement in pathological conditions, including cancer, is extensively studied. The upregulation of VEGFC expression in tumor cells promotes angiogenesis and lymphangiogenesis within the tumor microenvironment. This enhanced blood and lymphatic vessel formation facilitates tumor growth, invasion, and metastasis. Moreover, VEGFC can induce lymphangiogenesis in sentinel lymph nodes, aiding cancer cell dissemination. Targeting VEGFC signaling pathways has emerged as a potential therapeutic strategy to inhibit tumor angiogenesis and lymphangiogenesis, highlighting the clinical significance of understanding the complex interplay between VEGFC and cancer progression.
Several therapeutic interventions targeting VEGFC and its downstream signaling pathways are under investigation. Anti-VEGFC monoclonal antibodies, VEGFR inhibitors, and small molecule inhibitors of VEGFC-mediated signaling have shown promise in preclinical and clinical studies. These interventions aim to disrupt the angiogenic and lymphangiogenic processes driven by VEGFC, thereby inhibiting tumor growth, metastasis, and other pathological conditions associated with VEGFC dysregulation. Additionally, exploring combinational approaches with existing therapies, such as chemotherapy and immunotherapy, holds potential for synergistic effects and improved treatment outcomes. Continued research efforts are focused on optimizing these interventions for clinical application and expanding the therapeutic repertoire for VEGFC-associated diseases.
Multiple regulatory mechanisms control VEGFC expression levels. Transcriptional regulation plays a significant role, with various transcription factors binding to the VEGFC promoter region to activate or suppress its transcription. Additionally, post-transcriptional regulation through microRNAs and RNA-binding proteins can modulate VEGFC mRNA stability and translation efficiency. Furthermore, environmental factors, such as hypoxia and inflammation, influence VEGFC expression by activating specific signaling pathways. Understanding the precise regulatory mechanisms is crucial for deciphering the intricate balance required for maintaining proper VEGFC levels and ensuring its functional integrity.
Dysregulation of VEGFC has been associated with various pathological conditions. Excessive VEGFC expression has been implicated in tumor angiogenesis, promoting the growth and spread of cancer cells by stimulating the formation of blood and lymphatic vessels in the tumor microenvironment. On the other hand, decreased or insufficient VEGFC levels have been linked to lymphatic disorders, such as lymphedema, where impaired lymphatic vessel development results in fluid buildup and tissue swelling. Additionally, alterations in VEGFC signaling have been observed in ocular diseases, inflammatory disorders, and cardiovascular diseases. Understanding the dysregulation of VEGFC in these contexts may pave the way for potential therapeutic strategies targeting this protein.
VEGFC (Vascular Endothelial Growth Factor C) has diverse cellular functions. Primarily, it serves as a potent angiogenic factor, participating in neovascularization and lymphangiogenesis processes. VEGFC also regulates endothelial cell proliferation and migration, playing a crucial role in lymphatic dissemination and metastasis. Additionally, VEGFC is implicated in neurodevelopment, mammary gland morphogenesis, tissue regeneration, and other physiological processes. Its multifaceted functions highlight its significance in various biological contexts, emphasizing the need for further investigation to unravel its precise mechanisms and implications.
Customer Reviews (3)
Write a reviewEmbodied with the glorious power of scientific progress, the innovation behind this reagent inspires truly remarkable experimental encounters.
By requiring minimal usage, this protein reagent significantly reduces consumable costs, making it an ideal choice for large-scale experiments.
The manufacturer's proactive approach in offering valuable insights and suggestions has greatly improved the outcome of my experiments.
Ask a Question for All VEGFC Products
Required fields are marked with *
My Review for All VEGFC Products
Required fields are marked with *
Inquiry Basket